FierceBiotechOriginal article
{"a":[{"_":"Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins","$":{"href":"/biotech/spyre-snags-phase-2-win-il-23-antibody-round-ulcerative-colitis-program","hreflang":"en"}}]}
Phase 2positiveanti-IL-23 antibodyPositive
AI Analysis
Summary
Spyre's anti-IL-23 antibody achieved a phase 2 win for inflammatory bowel disease, marking the third positive phase 2 result in the company's three-pronged IBD strategy.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Phase 2 win for anti-IL-23 antibody in IBD
Importance:6/10
Sentiment:
0.70
IBDPhase 2 dataIL-23antibodyulcerative colitis
Read the original article
Published by FierceBiotech on September 8, 2026 9:46 AM